Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$706.41 -0.8%	$614.60	$510.05 ▼ $716.62	$43.23B	0.41	375,068 shs	348,854 shs
AXSM Axsome Therapeutics	$123.47 +1.8%	$108.99	$75.56 ▼ $139.13	$6.16B	0.54	765,802 shs	902,213 shs
AZTA Azenta	$30.16 -1.2%	$31.40	$23.91 ▼ $55.63	$1.38B	1.65	756,360 shs	530,830 shs
GS The Goldman Sachs Group	$729.93 -2.1%	$718.92	$439.38 ▼ $753.33	$220.97B	1.41	2.50 million shs	2.30 million shs
NARI Inari Medical	$79.97	$79.97	$39.76 ▼ $79.99	$4.68B	1.02	1.49 million shs	N/A
VCEL Vericel	$34.60 -4.8%	$38.10	$33.09 ▼ $63.00	$1.83B	1.33	502,594 shs	549,244 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+5.15%	+5.70%	+23.52%	+37.67%
AXSM Axsome Therapeutics	0.00%	+4.27%	+17.72%	+10.14%	+36.48%
AZTA Azenta	0.00%	-0.72%	-5.57%	+7.69%	-38.33%
GS The Goldman Sachs Group	0.00%	+0.93%	+5.09%	+23.40%	+46.10%
NARI Inari Medical	0.00%	0.00%	0.00%	0.00%	+84.99%
VCEL Vericel	0.00%	+1.59%	+2.05%	-12.53%	-29.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	3.6086 of 5 stars	2.5	2.0	0.0	0.0	2.7	1.7	4.4
AXSM Axsome Therapeutics	4.7473 of 5 stars	4.5	1.0	0.0	4.5	3.4	4.2	0.6
AZTA Azenta	3.1459 of 5 stars	2.2	3.0	0.0	0.0	3.7	2.5	2.5
GS The Goldman Sachs Group	4.6923 of 5 stars	2.2	4.0	4.2	3.0	2.2	2.5	2.5
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	2.3079 of 5 stars	3.5	0.0	0.0	0.0	3.5	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.09	Buy	$772.84	9.40% Upside
AXSM Axsome Therapeutics	3.07	Buy	$178.00	44.16% Upside
AZTA Azenta	2.40	Hold	$35.75	18.53% Upside
GS The Goldman Sachs Group	2.33	Hold	$660.00	-9.58% Downside
NARI Inari Medical	2.08	Hold	$69.38	-13.25% Downside
VCEL Vericel	3.00	Buy	$60.40	74.57% Upside

Current Analyst Ratings Breakdown

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	ARGX argenex	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$880.00 ➝ $887.00
8/26/2025	ARGX argenex	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$818.00
8/26/2025	ARGX argenex	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$750.00 ➝ $820.00
8/25/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$800.00
8/25/2025	ARGX argenex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$850.00
8/15/2025	GS The Goldman Sachs Group	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2025	AZTA Azenta	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$35.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/5/2025	AZTA Azenta	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	In-Line ➝ In-Line	$35.00 ➝ $33.00
8/4/2025	ARGX argenex	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$775.00 ➝ $830.00

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	19.20	$2.95 per share	239.76	$90.49 per share	7.81
AXSM Axsome Therapeutics	$385.69M	15.97	N/A	N/A	$1.18 per share	104.64
AZTA Azenta	$668.82M	2.07	$4.49 per share	6.71	$36.16 per share	0.83
GS The Goldman Sachs Group	$126.85B	1.74	$52.59 per share	13.88	$350.27 per share	2.08
NARI Inari Medical	$493.63M	9.48	$0.09 per share	906.95	$8.07 per share	9.91
VCEL Vericel	$249.12M	7.01	$0.30 per share	116.36	$5.92 per share	5.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$19.50	36.23	65.11	0.81	40.98%	21.06%	18.25%	10/30/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	43.78	N/A	-49.88%	-283.22%	-33.06%	11/11/2025 (Estimated)
AZTA Azenta	-$164.17M	-$2.42	N/A	32.78	N/A	-18.45%	1.35%	1.13%	11/11/2025 (Estimated)
GS The Goldman Sachs Group	$14.28B	$45.38	16.08	14.02	1.58	12.37%	14.32%	0.89%	10/14/2025 (Estimated)
NARI Inari Medical	-$1.64M	-$1.35	N/A	727.00	N/A	-13.68%	-10.09%	-6.60%	N/A
VCEL Vericel	$10.36M	$0.12	288.36	78.64	N/A	2.85%	2.47%	1.69%	11/6/2025 (Estimated)

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q3 2025	AZTA Azenta	$0.13	$0.19	+$0.06	-$1.15	$149.64 million	$143.94 million
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million
7/16/2025	Q2 2025	GS The Goldman Sachs Group	$9.82	$10.91	+$1.09	$10.91	$13.53 billion	$14.58 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
AZTA Azenta	$0.10	0.33%	N/A	N/A	N/A
GS The Goldman Sachs Group	$16.00	2.19%	N/A	35.26%	13 Years
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/14/2025	GS The Goldman Sachs Group	quarterly	$4.00	2.15%	8/29/2025	8/29/2025	9/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.60	5.27
AXSM Axsome Therapeutics	1.66	1.57	1.51
AZTA Azenta	N/A	2.76	2.44
GS The Goldman Sachs Group	2.57	0.67	0.67
NARI Inari Medical	N/A	1.77	1.40
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
AXSM Axsome Therapeutics	81.49%
AZTA Azenta	99.08%
GS The Goldman Sachs Group	71.21%
NARI Inari Medical	90.98%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
AXSM Axsome Therapeutics	22.40%
AZTA Azenta	10.62%
GS The Goldman Sachs Group	0.55%
NARI Inari Medical	10.60%
VCEL Vericel	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.72 million	Optionable
AZTA Azenta	3,100	45.84 million	40.97 million	Optionable
GS The Goldman Sachs Group	46,500	302.72 million	301.06 million	Optionable
NARI Inari Medical	800	58.54 million	52.34 million	Optionable
VCEL Vericel	300	50.46 million	46.83 million	Optionable

GS, VCEL, ARGX, AZTA, NARI, and AXSM Headlines

Recent News About These Companies

Vericel Corporation $VCEL Stock Position Decreased by Raymond James Financial Inc.

August 31 at 3:37 AM | marketbeat.com

Next Century Growth Investors LLC Boosts Stock Position in Vericel Corporation $VCEL

August 30 at 7:02 AM | marketbeat.com

Champlain Investment Partners LLC Lowers Stock Position in Vericel Corporation $VCEL

August 30 at 6:39 AM | marketbeat.com

Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

August 28, 2025 | markets.businessinsider.com

Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

August 28, 2025 | globenewswire.com

Nuveen LLC Purchases New Position in Vericel Corporation $VCEL

August 28, 2025 | marketbeat.com

Wellington Management Group LLP Acquires 74,723 Shares of Vericel Corporation $VCEL

August 25, 2025 | marketbeat.com

Russell Investments Group Ltd. Buys 31,635 Shares of Vericel Corporation $VCEL

August 25, 2025 | marketbeat.com

Analysts Set Vericel Corporation (NASDAQ:VCEL) PT at $60.33

August 24, 2025 | americanbankingnews.com

Vanguard Group Inc. Purchases 7,978 Shares of Vericel Corporation $VCEL

August 23, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Buy" by Brokerages

August 23, 2025 | marketbeat.com

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 98,005 Shares of Vericel Corporation $VCEL

August 20, 2025 | marketbeat.com

Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating

August 20, 2025 | msn.com

11 Best Small-Cap Growth Stocks to Buy Right Now

August 19, 2025 | insidermonkey.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Lord Abbett & CO. LLC

August 19, 2025 | marketbeat.com

Public Sector Pension Investment Board Grows Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

Invesco Ltd. Acquires 35,345 Shares of Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

LPL Financial LLC Has $2.92 Million Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Stock Position Reduced by Neuberger Berman Group LLC

August 17, 2025 | marketbeat.com

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13, 2025 | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GS, VCEL, ARGX, AZTA, NARI, and AXSM Company Descriptions

argenex NASDAQ:ARGX

$706.41 -5.79 (-0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$705.82 -0.58 (-0.08%)

As of 06:19 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Axsome Therapeutics NASDAQ:AXSM

$123.47 +2.19 (+1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$123.98 +0.51 (+0.41%)

As of 07:55 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Azenta NASDAQ:AZTA

$30.16 -0.38 (-1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$30.16 0.00 (0.00%)

As of 06:07 PM Eastern

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

The Goldman Sachs Group NYSE:GS

$729.93 -15.32 (-2.06%)

Closing price 03:59 PM Eastern

Extended Trading

$729.96 +0.02 (+0.00%)

As of 07:56 PM Eastern

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Inari Medical NASDAQ:NARI

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Vericel NASDAQ:VCEL

$34.60 -1.76 (-4.84%)

Closing price 04:00 PM Eastern

Extended Trading

$34.62 +0.02 (+0.06%)

As of 07:11 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Earnings

Compare Dividends

Latest GS, VCEL, ARGX, AZTA, NARI, and AXSM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GS, VCEL, ARGX, AZTA, NARI, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GS, VCEL, ARGX, AZTA, NARI, and AXSM Company Descriptions

argenex NASDAQ:ARGX

Axsome Therapeutics NASDAQ:AXSM

Azenta NASDAQ:AZTA

The Goldman Sachs Group NYSE:GS

Inari Medical NASDAQ:NARI

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools